Market Overview

Deutsche Bank Reports on Auxilium Pharmaceuticals (AUXL)


In a report released today, Deutsche Bank commented on Auxilium Pharmaceuticals (NASDAQ: AUXL). In the report, Deutsche Bank was bullish on the company.

Deutsche Bank writes, “Our Buy investment rating on Auxilium is predicated on the significant commercial opportunity for Xiaflex, coupled with a still solid growth outlook for Testim. We believe that Xiaflex, the company's potential flagship, non-surgical treatment for Dupuytren's contracture, could have peak sales potential of $400M+ in the US. Following the Q1 results, Auxilium shares continue to look attractive.”

Deutsche Bank has a Buy rating on the company and a price target of $28.00. Shares of the pharmaceutical closed at $22.55, down from the opening price of $22.27.

Posted-In: Auxilium Pharmaceuticals Deutsche BankAnalyst Color Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: J.P. Morgan Raising Price Target On Luminex (LMNX)

Encore Energy Partners Reports EPS of $0.76, May Not Be Comparable to $0.35 Estimate